Table 1.
Baseline characteristics of the study population and according to LIPI score (NSCLC: non-small-cell lung cancer; SCLC: small-cell lung cancer; HNSCC: head and neck squamous cell carcinoma; PD-(L)1: programmed death (ligand)1).
|
Overall Population, n = 191 (100%) |
LIPI Good n = 38 (23%) |
Intermediate LIPI n = 84 (51%) |
Poor LIPI n = 43 (26%) |
|
|---|---|---|---|---|
| Age | ||||
| median, range | 77 (70–93) | 78 (70–91) | 78 (70–93) | 76 (70–89) |
| Gender | ||||
| Female | 74 (39%) | 20 (52%) | 28 (33%) | 16 (37%) |
| Male | 117 (61%) | 18 (47%) | 56 (67%) | 27 (62%) |
| Cancer type | ||||
| Melanoma | 127 (66.5%) | 31(81.5%) | 58 (69%) | 31(72%) |
| Merkel cell | 2 (1%) | 0 (0%) | 2 (2.3%) | 0 (0%) |
| NSCLC | 29 (15%) | 4 (10.5%) | 10 (11.9%) | 7 (16.2%) |
| SCLC | 22 (11,5%) | 0 (0%) | 10 (11.9%) | 3 (6.9%) |
| Urothelial | 7 (3.6%) | 2 (5%) | 1 (1%) | 2 (4.6%) |
| HNSCC | 1 (0.5%) | 1 (2.6%) | 0 (0%) | 0 (0%) |
| Main sites of metastasis | ||||
| Skin | 37 (19.3%) | 7 (18.4%) | 19 (22.6%) | 7 (16.2%) |
| Lymph nodes | 84 (43.9%) | 14 (36.8%) | 38 (45.2%) | 25 (58.1%) |
| Lung | 71 (37%) | 11 (28.9%) | 28 (33.3%) | 23 (53.4%) |
| Liver | 37 (19.3%) | 4 (15.5%) | 14 (16.6%) | 12 (27.9%) |
| Bones | 49 (25.6%) | 8 (21%) | 18 (21.4%) | 12 (27.9%) |
| Adrenal glands | 20 (10.4%) | 3 (7.8%) | 8 (9.5%) | 3 (6.9%) |
| Kidney | 6 (3%) | 0 (0%) | 2 (2.3%) | 1 (2.3%) |
| Spleen | 8 (4%) | 4 (10.5%) | 3 (3.5%) | 1 (2.3%) |
| Gastrointestinal | 11 (5.7%) | 3 (7.8%) | 3 (3.5%) | 3 (6.9%) |
| Brain | 37 (19.3%) | 2 (5.2%) | 17 (20.2%) | 14 (32%) |
| Thyroid | 2 (1%) | 0 (0%) | 2 (2.3%) | 0 (0%) |
| Pancreas | 1 (0.5%) | 0 (0%) | 1 (1%) | 0 (0%) |
| Performance status ECOG | ||||
| 0–1 | 160 (84.2%) | 38 (100%) | 73 (88%) | 32 (74%) |
| ≥2 | 30 (15.7%) | 0(0%) | 10 (12%) | 11 (25.5%) |
| Missing | 1 (0.5%) | 0 (0%) | 1 (0.5%) | 0 (0%) |
| Line of treatment | ||||
| ≤2 | 170 (89%) | 36 (95%) | 79 (94%) | 33 (77%) |
| >2 | 21(11%) | 2 (5%) | 5 (6%) | 10 (23%) |
| Missing | 0 | 0 | 0 | 0 |
| Type of immunotherapy | ||||
| Anti PD1 | 182 (95.2%) | 36 (94.7%) | 81 (96.4%) | 41(95.3%) |
| Anti PD(L)1 | 9 (4.7%) | 2 (5.2%) | 3 (3.5%) | 2 (4.6%) |
| Types of anti PD(L)1 | ||||
| Avelumab | 2 (1%) | 0 (0%) | 2 (2.3%) | 0 (0%) |
| Atezolizumab | 7 (3.6%) | 2 (5.2%) | 1(1.1%) | 2 (4.6%) |
| Pembrolizumab | 114 (59.6%) | 29 (76.3%) | 50 (59.5%) | 28 (65%) |
| Nivolumab | 68 (35.6%) | 7(18.4%) | 31 (36.9%) | 13 (30.2%) |
| Steroids at baseline | ||||
| Dose >20 mg (prednisone equivalent) | 25 (13.3%) | 2 (5.2%) | 11(13.2%) | 8 (18.6%) |